Heron Therapeutics reports Q2 EPS (2c), consensus (1c)

Reports Q2 revenue $37.2M, consensus $38.08M. “As today’s release demonstrates, we enter the third quarter with strong momentum and a clear focus on accelerating the expansion of our core products,” said Craig Collard, Chief Executive Officer of Heron. “Our performance reflects the dedication of our team and the growing demand for innovative solutions that address critical patient needs. We remain committed to executing our strategic priorities, driving sustainable growth, and delivering long-term value to our stakeholders.”